Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma
Protocol ID
E7080-G000-230 (OLIE)
Disease (Sub Disease)
Solid tumours (Osteosarcoma)
Diagnosis Stage
Relapsed/ refractory
Location
NSW, QLD, VIC, WA, NZ
Sponsor
Eisai Inc.
Collaborators
Merck Sharp & Dohme Corp.
Trial Status
Open
Sites
The Children's Hospital at Westmead
Perth Children's Hospital
Queensland Children's Hospital
Royal Children's Hospital
Starship Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
2 Years to 25 Years
International registry ID's
NCT04154189
Back to Registry
Study Title A Multicenter Open-label Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma
Protocol ID E7080-G000-230 (OLIE)
Disease (Sub Disease) Solid tumours (Osteosarcoma)
Diagnosis Stage Relapsed/ refractory
Location NSW / QLD / VIC / WA / NZ
Sponsor Eisai Inc.
Collaborators Merck Sharp & Dohme Corp.
Links https://clinicaltrials.gov/ct2/show/NCT04154189
Trial Status Open
Trial Open Date 23/03/2020
Sites The Children's Hospital at Westmead / Perth Children's Hospital / Queensland Children's Hospital / Royal Children's Hospital / Starship Hospital
Study Type Treatment
Phase Phase 2
Age Eligibility 2 Years to 25 Years
International registry ID's NCT04154189